UBS Group’s Alexion Pharmaceuticals ALXN Stock Holding History

UBS Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-116,200	Closed	-$18.2M	–	9823
2020 Q4	$18.2M	Sell	116,200 -10,000	-8%	-$1.29M	0.01%	1405
2020 Q3	$14.4M	Hold	126,200	–	–	0.01%	1390
2020 Q2	$14.2M	Sell	126,200 -13,600	-10%	-$1.44M	0.01%	1277
2020 Q1	$12.6M	Buy	139,800 +136,300	+3,894%	+$13.4M	0.01%	1253
2019 Q4	$379K	Buy	+3,500	New	+$374K	﹤0.01%	5084
2019 Q1	–	Sell	-30,000	Closed	-$2.92M	–	8393
2018 Q4	$2.92M	Hold	30,000	–	–	﹤0.01%	2657
2018 Q3	$4.17M	Hold	30,000	–	–	﹤0.01%	2509
2018 Q2	$3.73M	Sell	30,000 -55,000	-65%	-$6.43M	﹤0.01%	2593
2018 Q1	$9.47M	Buy	85,000 +30,000	+55%	+$3.59M	﹤0.01%	1732
2017 Q4	$6.58M	Buy	55,000 +25,000	+83%	+$3.04M	﹤0.01%	2086
2017 Q3	$4.21M	Sell	30,000 -15,000	-33%	-$2.04M	﹤0.01%	2378
2017 Q2	$5.47M	Buy	+45,000	New	+$5.24M	﹤0.01%	2069
2016 Q3	–	Sell	-40,000	Closed	-$4.67M	–	8066
2016 Q2	$4.67M	Buy	+40,000	New	+$5.68M	﹤0.01%	2001
2016 Q1	–	Sell	-10,200	Closed	-$1.95M	–	8406
2015 Q4	$1.95M	Hold	10,200	–	–	﹤0.01%	2815
2015 Q3	$1.59M	Sell	10,200 -15,000	-60%	-$2.74M	﹤0.01%	2945
2015 Q2	$4.55M	Sell	25,200 -14,300	-36%	-$2.47M	﹤0.01%	2174
2015 Q1	$6.84M	Buy	39,500 +38,900	+6,483%	+$7.04M	﹤0.01%	1794
2014 Q4	$111K	Buy	+600	New	+$111K	﹤0.01%	5600

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

UBS Group's ALXN Position: Q3 2021 in Review

UBS Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 451,615 shares — an estimated $83M sold.

UBS Group first reported a position in ALXN in Q4 2014 and held it in 27 quarters. The position peaked at $144M in Q4 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

UBS Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
UBS Group sold 451,615 Alexion Pharmaceuticals shares in Q3 2021, an estimated $83M.
UBS Group first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 27 quarters.
UBS Group's Alexion Pharmaceuticals position peaked at $144M in Q4 2019.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on UBS Group's 13F filing for Q3 2021, filed 15 Nov 2021.